Young child with Doctor

AstraZeneca at a glance

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.

Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas.

Key facts

  • We employ around 51,500 people worldwide: 34.8% in Europe, 21.7% in North America, 6% in Central and South America, 4.1% in the Middle East and Africa and 33.4% in Asia Pacific.
  • We manufacture in 16 countries and are committed to ensuring a reliable supply of medicines where and when they are needed.
  • We work in over 100 countries and our medicines are used by millions of patients worldwide.
  • Our sales in 2012 totalled $25.7 billion

More facts are available in our 2013 Annual Report.

Annual Report 2013

AstraZeneca Annual Report 2013

Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to push the boundaries of science and deliver medicines that transform the lives of people around the world.